medRxiv preprint doi: https://doi.org/10.1101/2024.08.11.24311807; this version posted August 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

A new preprocedural predictive risk model for post-endoscopic retrograde cholangiopancreatography pancreatitis: The SuPER model

Mitsuru Sugimoto[1]*, Tadayuki Takagi[1], Tomohiro Suzuki[2], Hiroshi Shimizu[2], Goro Shibukawa[3], Yuki Nakajima[3], Yutaro Takeda[4], Yuki Noguchi MD[4], Reiko Kobayashi MD[4], Hidemichi Imamura[4], Hiroyuki Asama[5], Naoki Konno[5], Yuichi Waragai[6], Hidenobu Akatsuka[7], Rei Suzuki[1], Takuto Hikichi[8], and Hiromasa Ohira[1]

[1]Department of Gastroenterology, Fukushima Medical University, School of Medicine, Fukushima, Japan

[2]Department of Gastroenterology, Fukushima Rosai Hospital, Iwaki, Japan

[3]Department of Gastroenterology, Aizu Medical Center, Fukushima Medical University, Aizu, Japan

[4]Department of Gastroenterology, Ohta Nishinouchi Hospital, Koriyama, Japan

[5]Department of Gastroenterology, Fukushima Redcross Hospital, Fukushima, Japan

[6]Department of Gastroenterology, Soma General Hospital, Soma, Japan

[7]Department of Gastroenterology, Saiseikai Fukushima General Hospital, Fukushima, Japan

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2024.08.11.24311807; this version posted August 11, 2024. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

[8]Department of Endoscopy, Fukushima Medical University Hospital, Fukushima, Japan

*** For correspondence**

kita335@fmu.ac.jp

medRxiv preprint doi: https://doi.org/10.1101/2024.08.11.24311807; this version posted August 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Abstract

Background: Post–endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is a severe and deadly adverse event following ERCP. The ideal method for predicting PEP risk before ERCP has yet to be identified. We aimed to establish a simple PEP risk score model (SuPER model: Support for PEP Reduction) that can be applied before ERCP.

Methods: This multicenter study enrolled 2074 patients who underwent ERCP. Among them, 1037 patients each were randomly assigned to the development and validation cohorts. In the development cohort, the risk score model for predicting PEP was established by logistic regression analysis. In the validation cohort, the performance of the model was assessed.

Results: In the development cohort, five PEP risk factors that could be identified before ERCP were extracted and assigned weights according to their respective regression coefficients: -2 points for pancreatic calcification, 1 point for female sex, and 2 points for intraductal papillary mucinous neoplasm, a native papilla of Vater, or the use of pancreatic duct procedures. The PEP occurrence rate was 0% among low-risk patients (≤ 0 points), 5.5% among moderate-risk patients (1 to 3 points), and 20.2% among high-risk patients (4 to 7 points). In the validation cohort, the C-statistic of the risk score model was 0.71 (95% CI 0.64-0.78), which was considered acceptable. The PEP risk

medRxiv preprint doi: https://doi.org/10.1101/2024.08.11.24311807; this version posted August 11, 2024. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

classification (low, moderate, and high) was a significant predictive factor for PEP that was independent from intraprocedural PEP risk factors (precut sphincterotomy and inadvertent pancreatic duct cannulation) (OR 4.2, 95% CI 2.8-6.3, $P < 0.01$).

Conclusions: The PEP risk score allows an estimation of the risk of PEP prior to ERCP, regardless of whether the patient has undergone pancreatic duct procedures. This simple risk model, consisting of only five items, may aid in predicting and explaining the risk of PEP before ERCP and in preventing PEP by allowing selection of the appropriate expert endoscopist and useful PEP prophylaxes.

medRxiv preprint doi: https://doi.org/10.1101/2024.08.11.24311807; this version posted August 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Introduction

Endoscopic retrograde cholangiopancreatography (ERCP) is widely performed as an important diagnostic and therapeutic procedure for pancreaticobiliary diseases. ERCP-related procedures are relatively risky among endoscopic procedures. The high-risk adverse events of ERCP include duodenal perforation and bleeding after endoscopic sphincterotomy (EST) and post-ERCP pancreatitis (PEP). The rate of PEP occurrence is 3.1-13.0% (*Andriulli et al. , 2007, Freeman et al. , 1996, Glomsaker et al. , 2013, Katsinelos et al. , 2014, Kochar et al. , 2015, Loperfido et al. , 1998*). PEP can even become life-threatening. The fatality rate of PEP is 0.1–0.7% (*Andriulli et al. , 2007, Kochar et al. , 2015*). Therefore, the decision to perform ERCP should be made carefully, considering each patient's risk factors for PEP.

To predict an individual patient's PEP risk, five scoring systems have been devised (*Chiba et al. , 2021, DiMagno et al. , 2013, Friedland et al. , 2002, Fujita et al. , 2021, Zheng et al. , 2020*). The first risk scoring system for PEP occurrence was established in 2002. In that study, pain during the procedure, pancreatic duct cannulation, a history of PEP, and the number of cannulation attempts were identified as risk factors for PEP. After the first scoring system was reported, each new scoring system used risk factors that were extracted by multivariate analyses. These included various patient characteristics before ERCP and postprocedural risk factors. As

medRxiv preprint doi: https://doi.org/10.1101/2024.08.11.24311807; this version posted August 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

postprocedural risk factors, precut sphincterotomy and difficult cannulation were proposed, but it is difficult to predict these risk factors and to determine the PEP risk before ERCP. Thus, a new prediction scoring system for PEP before ERCP is desirable. If the risk of PEP could be predicted before ERCP, then the expert endoscopist can perform ERCP from the start, and high-PEP-risk procedures (for example, precut sphincterotomy, multiple cannulation attempts, inadvertent pancreatic duct cannulation) can be avoided (*Testoni et al. , 2010, Wang et al. , 2009*). If biliary cannulation without the use of at least one high-PEP-risk procedure is difficult, other treatments (for example, percutaneous transhepatic biliary drainage (PTBD) or endoscopic ultrasound (EUS)-guided biliary drainage (EUS-BD)) could be considered.

Therefore, we aimed to establish a PEP prediction model using only risk factors that can be gathered before ERCP. Our model was developed and validated with multicenter data from Japan.

Methods

We performed a multicenter retrospective study at six institutions in Japan. This study was approved by the institutional review board of Fukushima Medical University and that of each partner medical institution. All patients agreed to undergo ERCP after

medRxiv preprint doi: https://doi.org/10.1101/2024.08.11.24311807; this version posted August 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

providing written consent.

Patients

Among 2,176 patients who underwent ERCP between November 2020 and October 2022, 2,074 were enrolled in this study. The other 102 patients were excluded for the following reasons: past history of choledochojejunostomy, acute pancreatitis, choledochoduodenal fistula, difficulty finding the Vater papilla, past history of pancreatojejunostomy, or past history of pancreatogastrostomy (**Figure 1**).

Study design

We randomly sampled 50% of the patients as the development cohort and 50% as the validation cohort (**Figure 1**). In the development cohort, we established a risk scoring system for predicting PEP before ERCP, which was named the support for PEP reduction model (SuPER model). The validation cohort was used to confirm the effectiveness of the scoring system. PEP diagnosis and severity were assessed according to Cotton's criteria (*Cotton et al. , 1991*). Patients who experienced abdominal pain and had hyperamylasemia (more than three times the normal upper limit) at least 24 hours after ERCP were diagnosed with PEP. Mild PEP was defined as pancreatitis that

medRxiv preprint doi: https://doi.org/10.1101/2024.08.11.24311807; this version posted August 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

required prolongation of the planned hospitalization by 2-3 days. Moderate PEP was defined as pancreatitis that required 4-10 days of hospitalization. Severe PEP was defined as pancreatitis that required more than 10 days of hospitalization or intervention or hemorrhagic pancreatitis, phlegmon, or pseudocysts.

To establish the risk score, the risk factors for PEP were investigated using the data from the development cohort. To determine the PEP risk score, factors that might be associated with PEP occurrence were investigated. To predict the PEP risk score before ERCP, factors related to patient characteristics and previously scheduled procedures, as reported in past studies, were selected. The patients' risk factors included age < 50 years, female sex, a past history of pancreatitis, a past history of PEP, a past history of gastrectomy, pancreatic cancer, intraductal papillary mucinous neoplasm (IPMN), a native papilla of Vater, absence of chronic pancreatitis (CP), normal serum bilirubin (≤ 1.2 mg/dl), and periampullary diverticulum (*Ding et al. , 2015, Freeman et al. , 2001, Freeman et al. , 1996, Fujita et al. , 2022, Fujita et al. , 2021, Masci et al. , 2003, Wang et al. , 2009, Williams et al. , 2007, Zheng et al. , 2020*). Pancreatic divisum was excluded from the patient risk factor list because pancreatic divisum was observed in only two patients. Pancreatic calcification and a diameter of the main pancreatic duct > 3 mm were considered to indicate CP (*Beyer et al. , 2023, Sarner and Cotton, 1984*).

medRxiv preprint doi: https://doi.org/10.1101/2024.08.11.24311807; this version posted August 11, 2024. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

These imaging findings were confirmed by CT, MRI, or EUS before ERCP. The CT and MRI findings were reviewed by radiologists. IPMN was diagnosed according to the results of CT, MRI, and EUS. As pre-ERCP prophylaxes for PEP, gabexate or nafamostat, intravenous hydration, and NSAID suppositories were used (*Fujita et al. , 2022*). As planned procedure-related risk factors, EST, endoscopic papillary balloon dilation (EPBD), endoscopic papillary large balloon dilation (EPLBD) using a ≥ 12 mm balloon catheter (*Itoi et al. , 2018*), biliary stone removal, ampullectomy, biliary stent material (plastic stent, self-expandable metallic stent (SEMS), or covered SEMS (CSEMS)), inside stent placement, and procedures on the pancreatic duct were evaluated (*Freeman et al. , 2001, Freeman et al. , 1996, Harewood et al. , 2005, Kato et al. , 2022, Masci et al. , 2003, Masci et al. , 2001, Testoni et al. , 2010, Williams et al. , 2007*). A biliary stent above the Vater papilla was also assessed as a prophylactic measure against PEP (*Ishiwatari et al. , 2013*).

To demonstrate the independence of the established risk classification, the relationship between it and intraprocedural PEP risk factors (including precut sphincterotomy and inadvertent pancreatic duct cannulation) (*Testoni et al. , 2010, Wang et al. , 2009*) were investigated. Because of the retrospective nature of the data, the exact cannulation times and the number of cannulation attempts were not available.

medRxiv preprint doi: https://doi.org/10.1101/2024.08.11.24311807; this version posted August 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Therefore, multiple cannulation attempts and a prolonged cannulation time could not be investigated as intraprocedural PEP risk factors.

Sample size

The primary aim of this study was to establish a PEP prediction model that could be used to calculate a risk score before ERCP. To construct a prediction model by logistic regression analysis, 10 events per explanatory variable were needed (*Wynants et al. , 2015*). Seven variables were evaluated in the development cohort, so 70 PEP patients were required. Five variables were evaluated in the validation cohort, so 50 PEP patients were necessary for it. According to a previous systematic review, the rate of PEP occurrence was 9.7% (*Kochar et al. , 2015*). Therefore, at least 722 and 521 patients were included in the development and validation cohorts, respectively.

Statistical analysis

In the development cohort, univariate and multivariate logistic regression analyses were performed to identify the risk factors for PEP. The factors that had a p value < 0.10 in the univariate analysis were included in the multivariate analysis. To construct the scoring system for PEP risk, the factors with $p < 0.10$ in the multivariate analysis were

medRxiv preprint doi: https://doi.org/10.1101/2024.08.11.24311807; this version posted August 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

ultimately included in the risk score model. The factors selected in the multivariate analysis were assigned points according to the regression coefficient (each variable's risk points = the ratio of the variable's regression coefficient/minimum regression coefficient). The sum of the assigned points was calculated for each patient, and the patients were classified into three groups (low risk, moderate risk, and high risk) according to the expected rate of PEP occurrence (*Friedland et al. , 2002*). The risk classification system (SuPER model) was also applied to the validation cohort.

With respect to both the development and validation cohorts, the effectiveness of the risk score model was evaluated as follows. The correlations between the risk score, risk classification and PEP occurrence were evaluated by the Cochran–Armitage trend test. The predictive accuracy of the risk score was assessed using the C statistic. The goodness of fit of the model was evaluated using the Hosmer–Lemeshow test. The independence of the established risk classification from the unexpected intraprocedural PEP risk factors was assessed by multivariate logistic regression analyses.

Patients with missing data for variables selected in the risk score model were removed from the final cohort.

Statistical analyses were performed using EZR version 1.62 (Saitama Medical Centre, Jichi Medical University, Saitama, Japan) and SPSS version 26.0 (IBM Corp.,

medRxiv preprint doi: https://doi.org/10.1101/2024.08.11.24311807; this version posted August 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Armonk, NY, USA). A p value < 0.05 indicated statistical significance.

Results

Patient characteristics and ERCP outcomes in each cohort

The patient characteristics and ERCP outcomes in each cohort are shown in **Table 1**. A total of 1037 patients were assigned to each of the development and validation cohorts, including 70 (6.8%) and 64 (6.2%) patients diagnosed with PEP, respectively. The pre-ERCP prophylactic measures used at each hospital differed, and not all patients received prophylaxis.

Construction of the PEP risk scoring system

According to the univariate analyses, age < 50 years, female sex, IPMN, a native papilla of Vater, pancreatic calcification, EST, and procedures on the pancreatic duct had p values < 0.10 (**Table 2**). According to the multivariate analysis, female sex, IPMN, a native papilla of Vater, pancreatic calcification, and procedures on the pancreatic duct had p values < 0.10. These factors were assigned risk points according to their respective regression coefficients.

medRxiv preprint doi: https://doi.org/10.1101/2024.08.11.24311807; this version posted August 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

The risk score of each patient was calculated as the total of that patient's risk points and ranged from -2 to 7 points (**Table 3**). The risk score was found to be correlated with PEP occurrence ($p < 0.01$, Cochran–Armitage trend test). The patients were classified as low (≤ 0 points), moderate (1-3 points), or high risk (4-7 points) for PEP according to the risk score. The PEP rates were 0% (0/327) among the low-risk patients, 5.5% (27/492) among the moderate-risk patients, and 20.2% (39/193) among the high-risk patients. The risk classification was correlated with PEP occurrence ($p < 0.01$, Cochran–Armitage trend test).

The C statistic of the risk score model was sufficiently high at 0.77 (95% confidence interval (CI) 0.72-0.82) (**Table 4**). The goodness of fit of the risk score model was also confirmed by the Hosmer–Lemeshow test ($p = 0.59$).

Validation of the PEP risk scoring system

The risk score was associated with PEP occurrence in the validation cohort ($p < 0.01$, Cochran–Armitage trend test) (**Table 3**). We found that 2.4% (8/331) of the patients at low risk, 5.3% (27/513) of those at moderate risk, and 18.0% (29/161) of those at high risk experienced PEP. The risk classification was also correlated with PEP occurrence in the validation cohort ($p < 0.01$, Cochran–Armitage trend test).

medRxiv preprint doi: https://doi.org/10.1101/2024.08.11.24311807; this version posted August 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

The C statistic of the risk score was 0.71, which was also high in the validation cohort (**Table 4**). The PEP risk score model showed good fitness according to the Hosmer–Lemeshow test (p = 0.40). According to the above results, the preprocedural PEP risk could be calculated, as shown in **Figure 2**.

Risk classification and unexpected PEP risk factors

The relation between the established risk classification and intraprocedural PEP risk factors is shown in **Appendix 1−table 1**. In all patients, the development cohort, and the validation cohort, the risk classification was significantly associated with the occurrence of PEP. On the other hand, precut sphincterotomy and inadvertent pancreatic duct cannulation were not significantly associated with the occurrence of PEP.

Discussion

In this multicenter study, we created a risk scoring system (the SuPER model) using five items that could be measured before performing ERCP. With this score, PEP occurrence could be accurately predicted to some degree. Besides, the established PEP risk classification was associated with PEP occurrence independently from unpredictable intraprocedural PEP risk procedures.

medRxiv preprint doi: https://doi.org/10.1101/2024.08.11.24311807; this version posted August 11, 2024. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

This risk scoring and classification of PEP has several advantages. First, the score is calculated using only five items, all of which can be easily assessed by medical interviews and imaging (for example, CT). One scoring system included sphincter of Oddi dysfunction (SOD) as a test item (*DiMagno et al. , 2013*). The diagnosis of SOD requires sphincter of Oddi manometry and fulfilment of the criteria for biliary pain, but sphincter of Oddi manometry is not widely used (*Cotton et al. , 2016*). The diagnostic criterion for biliary pain included 8 items, and that for SOD included 15 items. Among the items of the SuPER risk scoring system, pancreatic calcification was assigned -2 points. Its low weighting could be explained by the following. The international conceptual model of CP can be divided into four stages: acute pancreatitis–recurrent acute pancreatitis, early CP, established CP, and end-stage CP (*Whitcomb et al. , 2016*). Established CP patients have already passed the acute pancreatitis–recurrent acute pancreatitis course, and pancreatic calcification has been reported in established CP patients. Acinar dysfunction has also been observed in these patients (*Whitcomb et al. , 2016*). Therefore, patients with pancreatic calcification may have a lower incidence of PEP.

Second, the SuPER risk score can be determined before the ERCP procedure, as the established risk classification was found to be the sole significant factor

medRxiv preprint doi: https://doi.org/10.1101/2024.08.11.24311807; this version posted August 11, 2024. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

predicting the occurrence of PEP independent from intraprocedural PEP risk factors. As described in the Background section, precut sphincterotomy, multiple cannulation attempts, and a cannulation time greater than 10 minutes were identified as high risk factors that cannot be accounted for prior to ERCP (*Testoni et al. , 2010, Wang et al. , 2009*). Although the established PEP risk classification was independent from the included intraprocedural risk factors (precut sphincterotomy and inadvertent pancreatic duct cannulation), detailed data on the number of cannulation attempts and the cannulation time were not available. Therefore, to avoid intraoperative procedures associated with a high risk of PEP occurrence, an expert endoscopist can initially perform ERCP for high-PEP-risk patients. In addition, PEP prophylaxis can be administered beforehand for high-PEP-risk patients. As effective prophylaxes for PEP, rectal NSAIDS and pancreatic stent placement have been reported (*Elmunzer et al. , 2008, Murray et al. , 2003, Sugimoto et al. , 2019*). In this report, rectal NSAID use was not identified as a significant factor preventing PEP. One reason for this is that in past reports describing the use of rectal NSAIDs to prevent PEP, patients at high risk for PEP were often treated (*Elmunzer et al. , 2008*). In contrast, this study included all patients who underwent ERCP. Another reason might be the difference in dose. One hundred milligrams of rectal diclofenac was used in past reports, whereas 12.5-50 mg of

medRxiv preprint doi: https://doi.org/10.1101/2024.08.11.24311807; this version posted August 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

diclofenac was used in this study. In Japan, the approved diclofenac dose covered by insurance is 50 mg or less, with the dose being typically lower for elderly patients. Therefore, diclofenac doses of 12.5-50 mg were prescribed by the doctors depending on the age and size of the patients. Pancreatic stent placement itself is one of the procedures performed on the pancreatic duct and was a higher-risk procedure for PEP than endoscopic biliary procedures without an approach to the pancreatic duct (**Appendix 2−table 2**). Moreover, pancreatic stent placement has become a prophylactic treatment for PEP in patients who have undergone pancreatography or wire placement to the pancreatic duct (*Mazaki et al. , 2014, Sugimoto et al. , 2019*). As described above, pancreatic stent placement was performed along with high-risk-PEP procedures (i.e., guidewire placement to the pancreatic duct or pancreatography); therefore, pancreatic stent placement was grouped together with the other endoscopic retrograde pancreatography procedures as “procedures on the pancreatic duct”.

This study has several limitations. First, the study was retrospective, and there were missing data. However, the results reported are trustworthy. The percentage of patients who did not meet the inclusion criteria was not more than 5%, and the percentage of missing data was not over 1%. As described in the Materials and Methods section, patients with missing data for the variables selected in the risk score model

medRxiv preprint doi: https://doi.org/10.1101/2024.08.11.24311807; this version posted August 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

were removed from the final cohort. The reliability of the SuPER risk score model was also statistically confirmed. Second, some factors cannot be assessed before ERCP. Additional procedures could be conducted during ERCP, and unplanned pancreatography is often performed in patients who are scheduled for endoscopic cholangiography or biliary treatment. However, the established PEP risk classification was independent from the included intraprocedural risk factors. A planned procedure for accessing the pancreatic duct is listed in the SuPER risk model. Therefore, we can predict the SuPER risk score and classification of patients regardless of whether they have undergone pancreatic duct procedures. Third, this study was performed in a single country. Validation studies over wider geographic regions are necessary.

In conclusion, a simple and useful PEP scoring system (SuPER model) with only five clinical items was developed in this multicenter study. This scoring system may aid in predicting and explaining PEP risk and in selecting appropriate prophylaxes for PEP and endoscopic pancreaticobiliary procedures for each patient.

Acknowledgements

We thank all the staff at the Department of Gastroenterology of Fukushima Medical University, the Department of Endoscopy of Fukushima Medical University Hospital,

medRxiv preprint doi: https://doi.org/10.1101/2024.08.11.24311807; this version posted August 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

the Department of Gastroenterology of Fukushima Rosai Hospital, the Department of Gastroenterology of Aizu Medical Center, Fukushima Medical University, the Department of Gastroenterology of Ohtanishinouchi Hospital, Koriyama, the Department of Gastroenterology of Fukushima Redcross Hospital, the Department of Gastroenterology of Soma General Hospital, the Department of Gastroenterology of Saiseikai Fukushima General Hospital, and the Gastroenterology Ward of Fukushima Medical University Hospital. We also thank American Journal Experts for providing English language editing services.

Additional information

Competing interests

The authors declare that they have no competing interests to report.

Funding

None.

Author contributions

medRxiv preprint doi: https://doi.org/10.1101/2024.08.11.24311807; this version posted August 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

M.S. wrote the paper, designed and performed the research. T.T. wrote the paper, designed and oversaw the research. T.S., H.S., G.S., Y.S., Y.N., Y.T., Y.N., R.K., H.I., H.A., N.K., Y.W., and H.A. performed the research. R.S. provided clinical advice. T.H. supervised the report. H.O. supervised the report and the writing of the paper. All authors read and approved the final manuscript.

Ethics

The study protocol was reviewed and approved by the Institutional Review Board of Fukushima Medical University (Number 2453). The analysis used anonymous clinical data obtained after all the participants agreed to treatment by written consent, so patients were not required to give informed consent for the study. The details of the study can be found on the homepage of Fukushima Medical University.

Data availability

The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.

medRxiv preprint doi: https://doi.org/10.1101/2024.08.11.24311807; this version posted August 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

References

Andriulli A, Loperfido S, Napolitano G, Niro G, Valvano MR, Spirito F, Pilotto A, Forlano R. 2007. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. *American Journal of Gastroenterology* **102**:1781-1788. DOI: 10.1111/j.1572-0241.2007.01279.x

Beyer G, Kasprowicz F, Hannemann A, Aghdassi A, Thamm P, Volzke H, Lerch MM, Kühn JP, Mayerle J. 2023. Definition of age-dependent reference values for the diameter of the common bile duct and pancreatic duct on MRCP: a population-based, cross-sectional cohort study. *Gut* **72**:1738-1744. DOI: 10.1136/gutjnl-2021-326106, PMID: PMC10423481

Chiba M, Kato M, Kinoshita Y, Shimamoto N, Tomita Y, Abe T, Kanazawa K, Tsukinaga S, Nakano M, Torisu Y, Toyoizumi H, Sumiyama K. 2021. The milestone for preventing post-ERCP pancreatitis using novel simplified predictive scoring system: a propensity score analysis. *Surgical Endoscopy* **35**:6696-6707. DOI: 10.1007/s00464-020-08173-4

Cotton PB, Elta GH, Carter CR, Pasricha PJ, Corazziari ES. 2016. Rome IV. Gallbladder and Sphincter of Oddi Disorders. *Gastroenterology*. DOI: 10.1053/j.gastro.2016.02.033

medRxiv preprint doi: https://doi.org/10.1101/2024.08.11.24311807; this version posted August 11, 2024. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Cotton PB, Lehman G, Vennes J, Geenen JE, Russell RC, Meyers WC, Liguory C, Nickl N. 1991. Endoscopic sphincterotomy complications and their management: an attempt at consensus. *Gastrointestinal Endoscopy* **37**:383-393

DiMagno MJ, Spaete JP, Ballard DD, Wamsteker EJ, Saini SD. 2013. Risk models for post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP): smoking and chronic liver disease are predictors of protection against PEP. *Pancreas* **42**:996-1003. DOI: 10.1097/MPA.0b013e31827e95e9, PMID: PMC3701741

Ding X, Zhang F, Wang Y. 2015. Risk factors for post-ERCP pancreatitis: A systematic review and meta-analysis. *Surgeon* **13**:218-229. DOI: 10.1016/j.surge.2014.11.005

Elmunzer BJ, Waljee AK, Elta GH, Taylor JR, Fehmi SM, Higgins PD. 2008. A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. *Gut* **57**:1262-1267. DOI: 10.1136/gut.2007.140756

Freeman ML, DiSario JA, Nelson DB, Fennerty MB, Lee JG, Bjorkman DJ, Overby CS, Aas J, Ryan ME, Bochna GS, Shaw MJ, Snady HW, Erickson RV, Moore JP, Roel JP. 2001. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. *Gastrointestinal Endoscopy* **54**:425-434

medRxiv preprint doi: https://doi.org/10.1101/2024.08.11.24311807; this version posted August 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Freeman ML, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ, Moore JP, Fennerty MB, Ryan ME, Shaw MJ, Lande JD, Pheley AM. 1996. Complications of endoscopic biliary sphincterotomy. *New England Journal of Medicine* **335**:909-918. DOI: 10.1056/nejm199609263351301

Friedland S, Soetikno RM, Vandervoort J, Montes H, Tham T, Carr-Locke DL. 2002. Bedside scoring system to predict the risk of developing pancreatitis following ERCP. *Endoscopy* **34**:483-488. DOI: 10.1055/s-2002-32004

Fujita K, Yazumi S, Matsumoto H, Asada M, Nebiki H, Matsumoto K, Maruo T, Takenaka M, Tomoda T, Onoyama T, Kurita A, Ueki T, Katayama T, Kawamura T, Kawamoto H. 2022. Multicenter prospective cohort study of adverse events associated with biliary endoscopic retrograde cholangiopancreatography: Incidence of adverse events and preventive measures for post-endoscopic retrograde cholangiopancreatography pancreatitis. *Digestive Endoscopy* **34**:1198-1204. DOI: 10.1111/den.14225, PMID: PMC9540598

Fujita K, Yazumi S, Uza N, Kurita A, Asada M, Kodama Y, Goto M, Katayama T, Anami T, Watanabe A, Sugahara A, Mukai H, Kawamura T. 2021. New practical scoring system to predict post-endoscopic retrograde cholangiopancreatography pancreatitis: Development and validation. *JGH Open* **5**:1078-1084. DOI:

medRxiv preprint doi: https://doi.org/10.1101/2024.08.11.24311807; this version posted August 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

10.1002/jgh3.12634, PMID: PMC8454475

Glomsaker T, Hoff G, Kvaloy JT, Soreide K, Aabakken L, Soreide JA. 2013. Patterns and predictive factors of complications after endoscopic retrograde cholangiopancreatography. *Br J Surg* **100**:373-380. DOI: 10.1002/bjs.8992

Harewood GC, Pochron NL, Gostout CJ. 2005. Prospective, randomized, controlled trial of prophylactic pancreatic stent placement for endoscopic snare excision of the duodenal ampulla. *Gastrointestinal Endoscopy* **62**:367-370. DOI: 10.1016/j.gie.2005.04.020

Ishiwatari H, Hayashi T, Ono M, Sato T, Kato J. 2013. Newly designed plastic stent for endoscopic placement above the sphincter of Oddi in patients with malignant hilar biliary obstruction. *Digestive Endoscopy* **25 Suppl 2**:94-99. DOI: 10.1111/den.12080

Itoi T, Ryozawa S, Katanuma A, Okabe Y, Kato H, Horaguchi J, Tsuchiya T, Gotoda T, Fujita N, Yasuda K, Igarashi Y, Fujimoto K. 2018. Japan Gastroenterological Endoscopy Society guidelines for endoscopic papillary large balloon dilation. *Digestive Endoscopy* **30**:293-309. DOI: 10.1111/den.13029

Kato S, Kuwatani M, Onodera M, Kudo T, Sano I, Katanuma A, Uebayashi M, Eto K, Fukasawa M, Hashigo S, Iwashita T, Yoshida M, Taya Y, Kawakami H, Kato H,

medRxiv preprint doi: https://doi.org/10.1101/2024.08.11.24311807; this version posted August 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Nakai Y, Kobashigawa K, Kawahata S, Shinoura S, Ito K, Kubo K, Yamato H, Hara K, Maetani I, Mukai T, Shibukawa G, Itoi T. 2022. Risk of Pancreatitis Following Biliary Stenting With/Without Endoscopic Sphincterotomy: A Randomized Controlled Trial. *Clinical Gastroenterology and Hepatology* **20**:1394-1403 e1391. DOI: 10.1016/j.cgh.2021.08.016

Katsinelos P, Lazaraki G, Chatzimavroudis G, Gkagkalis S, Vasiliadis I, Papaeuthimiou A, Terzoudis S, Pilpilidis I, Zavos C, Kountouras J. 2014. Risk factors for therapeutic ERCP-related complications: an analysis of 2,715 cases performed by a single endoscopist. *Ann Gastroenterol* **27**:65-72, PMID: PMC3959534

Kochar B, Akshintala VS, Afghani E, Elmunzer BJ, Kim KJ, Lennon AM, Khashab MA, Kalloo AN, Singh VK. 2015. Incidence, severity, and mortality of post-ERCP pancreatitis: a systematic review by using randomized, controlled trials. *Gastrointestinal Endoscopy* **81**:143-149 e149. DOI: 10.1016/j.gie.2014.06.045

Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De Berardinis F, De Bernardin M, Ederle A, Fina P, Fratton A. 1998. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. *Gastrointest Endosc* **48**:1-10

Masci E, Mariani A, Curioni S, Testoni PA. 2003. Risk factors for pancreatitis following

medRxiv preprint doi: https://doi.org/10.1101/2024.08.11.24311807; this version posted August 11, 2024. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

endoscopic retrograde cholangiopancreatography: a meta-analysis. *Endoscopy* **35**:830-834. DOI: 10.1055/s-2003-42614

Masci E, Toti G, Mariani A, Curioni S, Lomazzi A, Dinelli M, Minoli G, Crosta C, Comin U, Fertitta A, Prada A, Passoni GR, Testoni PA. 2001. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. *American Journal of Gastroenterology* **96**:417-423. DOI: 10.1111/j.1572-0241.2001.03594.x

Mazaki T, Mado K, Masuda H, Shiono M. 2014. Prophylactic pancreatic stent placement and post-ERCP pancreatitis: an updated meta-analysis. *Journal of Gastroenterology* **49**:343-355. DOI: 10.1007/s00535-013-0806-1

Murray B, Carter R, Imrie C, Evans S, O'Suilleabhain C. 2003. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. *Gastroenterology* **124**:1786-1791. DOI: 10.1016/s0016-5085(03)00384-6

Sarner M, Cotton PB. 1984. Classification of pancreatitis. *Gut* **25**:756-759. DOI: 10.1136/gut.25.7.756, PMID: PMC1432589

Sugimoto M, Takagi T, Suzuki R, Konno N, Asama H, Sato Y, Irie H, Watanabe K, Nakamura J, Kikuchi H, Takasumi M, Hashimito M, Hikichi T, Ohira H. 2019.

medRxiv preprint doi: https://doi.org/10.1101/2024.08.11.24311807; this version posted August 11, 2024. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Pancreatic stents to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis: A meta-analysis. *World J Metaanal* **7**:249-258

Testoni PA, Mariani A, Giussani A, Vailati C, Masci E, Macarri G, Ghezzo L, Familiari L, Giardullo N, Mutignani M, Lombardi G, Talamini G, Spadaccini A, Briglia R, Piazzi L. 2010. Risk factors for post-ERCP pancreatitis in high- and low-volume centers and among expert and non-expert operators: a prospective multicenter study. *American Journal of Gastroenterology* **105**:1753-1761. DOI: 10.1038/ajg.2010.136

Wang P, Li ZS, Liu F, Ren X, Lu NH, Fan ZN, Huang Q, Zhang X, He LP, Sun WS, Zhao Q, Shi RH, Tian ZB, Li YQ, Li W, Zhi FC. 2009. Risk factors for ERCP-related complications: a prospective multicenter study. *American Journal of Gastroenterology* **104**:31-40. DOI: 10.1038/ajg.2008.5

Whitcomb DC, Frulloni L, Garg P, Greer JB, Schneider A, Yadav D, Shimosegawa T. 2016. Chronic pancreatitis: An international draft consensus proposal for a new mechanistic definition. *Pancreatology* **16**:218-224. DOI: 10.1016/j.pan.2016.02.001, PMID: PMC6042966

Williams EJ, Taylor S, Fairclough P, Hamlyn A, Logan RF, Martin D, Riley SA, Veitch

medRxiv preprint doi: https://doi.org/10.1101/2024.08.11.24311807; this version posted August 11, 2024. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

P, Wilkinson ML, Williamson PR, Lombard M. 2007. Risk factors for complication following ERCP; results of a large-scale, prospective multicenter study. *Endoscopy* **39**:793-801. DOI: 10.1055/s-2007-966723

Wynants L, Bouwmeester W, Moons KG, Moerbeek M, Timmerman D, Van Huffel S, Van Calster B, Vergouwe Y. 2015. A simulation study of sample size demonstrated the importance of the number of events per variable to develop prediction models in clustered data. *Journal of Clinical Epidemiology* **68**:1406-1414. DOI: 10.1016/j.jclinepi.2015.02.002

Zheng R, Chen M, Wang X, Li B, He T, Wang L, Xu G, Yao Y, Cao J, Shen Y, Wang Y, Zhu H, Zhang B, Wu H, Zou X, He G. 2020. Development and validation of a risk prediction model and scoring system for post-endoscopic retrograde cholangiopancreatography pancreatitis. *Ann Transl Med* **8**:1299. DOI: 10.21037/atm-20-5769, PMID: PMC7661903

medRxiv preprint doi: https://doi.org/10.1101/2024.08.11.24311807; this version posted August 11, 2024. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Figure legends

Figure 1. Flowchart of the inclusion criteria. ERCP, endoscopic retrograde cholangiopancreatography.

Figure 2. Example of the preprocedural PEP risk checklist. ERCP, endoscopic retrograde cholangiopancreatography. IPMN, intraductal papillary mucinous neoplasm; PEP, post-ERCP pancreatitis.

medRxiv preprint doi: https://doi.org/10.1101/2024.08.11.24311807; this version posted August 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Tables

Table 1. Comparison of patient characteristics and ERCP outcomes between the development and validation cohorts.

	Development cohort (n=1037)	Validation cohort (n=1037)	*P* value
Patient factors			
Age, y, mean ± SD	73.8 ± 12.7	75.1 ± 12.5	0.02
Sex, n, male/female	642/395	629/408	0.59
History of pancreatitis, n (%)	73 (7.0)	45 (4.4)	0.01
History of PEP, n (%)	26 (2.5)	24 (2.3)	0.89
History of gastrectomy, n (%)	82 (7.9)	88 (8.5)	0.69
Billroth-I reconstruction, n	24	25	
Billroth-II reconstruction, n	23	25	
Roux-en-Y reconstruction, n	33	36	
Double tract, n	1	1	
Gastric tube reconstruction, n	1	1	
Pancreatic cancer, n (%)	145 (14.0)	174 (16.8)	0.09
IPMN, n (%)	17 (1.6)	8 (0.8)	0.11
Native papilla of Vater, n (%)	535 (51.6)	494 (47.7)	0.08
Total bilirubin, mg/dl, mean ± SD	3.5 ± 5.3	3.6 ± 5.0	0.45
Diameter of the MPD, mm, mean ± SD [a]	2.84 ± 2.63	3.1 ± 2.9	0.10
Pancreatic calcification, n (%) [b]	107 (10.6)	87 (8.7)	0.15
Periampullary diverticulum, n (%)	207 (20.0)	224 (21.6)	0.39
Pre-ERCP prophylaxis			
Gabexate or Nafamostat, n (%)	709 (68.4)	703 (67.8)	0.81
Intravenous hydration, n (%)	22 (2.1)	14 (1.4)	0.24
NSAID suppository, n (%)	53 (5.1)	45 (4.3)	0.47
Factors related to the planned procedure			
EST, n (%)	449 (43.3)	434 (41.9)	0.53
EPBD, n (%)	31 (3.0)	40 (3.9)	0.33
EPLBD, n (%)	56 (5.4)	55 (5.3)	1.0
Biliary stone removal, n (%)	327 (31.5)	342 (33.0)	0.51

medRxiv preprint doi: https://doi.org/10.1101/2024.08.11.24311807; this version posted August 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Ampullectomy, n (%)	5 (0.5)	5 (0.5)	1.0
Biliary stent, n (%)	594 (57.3)	611(58/9)	0.48
Plastic stent, n (%)	445 (42.9)	436 (42.0)	0.72
SEMS, n (%)	119 (11.5)	122 (11.8)	0.89
CSEMS, n (%)	36 (3.5)	44 (4.2)	0.43
Biliary stent above the papilla, n (%)	45 (4.3)	47 (4.5)	0.92
Procedures on the pancreatic duct, n (%)	285 (27.5)	237 (22.9)	0.017
PEP occurrence, n (%)	70 (6.8)	64 (6.2)	0.66
Mild, n	60	53	
Moderate, n	8	7	
Severe, n	2	4	

ERCP, endoscopic retrograde cholangiopancreatography; SD, standard deviation; PEP, post-ERCP pancreatitis; IPMN, intraductal papillary mucinous neoplasm; MPD, main pancreatic duct; EST, endoscopic sphincterotomy; EPBD, endoscopic papillary balloon dilation; SEMS, self-expandable metallic stent; CSEMS, covered SEMS.

[a] Data were available for 1671 patients.

[b] Data were available for 2017 patients.

500 **Table 2.** Logistic regression analysis of predictive factors for PEP in the development cohort.

	Univariate analysis			Multivariate analysis				
	OR	95% CI	*P* value	OR	95% CI	*P* value	Regression coefficient	Points
Age < 50 years	2.42	0.99-6.0	0.053	1.76	0.67-4.63	0.25	0.56	-
Female	1.91	1.17-3.10	<0.01	1.72	1.03-2.89	0.039	0.55	1
History of pancreatitis	1.26	0.53-3.0	0.61					
History of PEP	1.84	0.54-6.28	0.33					
History of gastrectomy	0.89	0.35-2.27	0.81					
Pancreatic cancer	1.03	0.51-2.06	0.94					
IPMN	8.15	2.92-22.7	<0.01	3.04	0.97-9.52	0.056	1.11	2
Native papilla of Vater	4.49	2.42-8.30	<0.01	2.72	1.30-5.71	<0.01	1.0	2
Total bilirubin ≤ 1.2 mg/dl	1.13	0.69-1.84	0.62					
Diameter of the MPD > 3 mm [a]	1.31	0.76-2.25	0.33					
Pancreatic calcification [b]	0.36	0.11-1.17	0.089	0.32	0.10-1.1	0.072	-1.13	-2
Periampullary diverticulum	0.65	0.33-1.30	0.22					
Gabexate or Nafamostat	0.72	0.44-1.19	0.20					
Intravenous hydration	1.39	0.32-6.08	0.66					
NSAID suppository before ERCP	1.47	0.57-3.83	0.43					
EST	1.71	1.05-2.79	0.03	0.83	0.45-1.52	0.54	-0.19	-
EPBD	< 0.01	0-Infinity	0.98					
EPLBD	0.24	0.03-1.76	0.16					
Biliary stone removal	0.68	0.39-1.19	0.18					

Ampullectomy	3.49	0.39-31.6	0.27					
Biliary stent	0.93	0.57-1.52	0.78					
Plastic stent	0.72	0.44-1.20	0.21					
SEMS	1.66	0.87-3.20	0.13					
CSEMS	0.81	0.19-3.43	0.77					
Biliary stent above the papilla	0.30	0.04-2.24	0.24					
Procedures on the pancreatic duct	4.77	2.89-7.89	<0.01	3.49	1.99-6.12	<0.01	1.25	2

PEP, post–endoscopic retrograde cholangiopancreatography pancreatitis; OR, odds ratio; CI, confidence interval; IPMN, intraductal papillary mucinous neoplasm; MPD, main pancreatic duct; EST, endoscopic sphincterotomy; EPBD, endoscopic papillary balloon dilation; EPLBD, endoscopic papillary large balloon dilation; SEMS, self-expandable metallic stent; CSEMS, covered SEMS.

[a] Data were available for 985 patients in the development cohort.

[b] Data were available for 1012 patients in the development cohort.

Table 3. Patient distribution in terms of risk score and classification.

Risk score		Development cohort (n = 1012) [a]			Validation cohort (n = 1005) [b]		
		PEP occurrence, N	PEP rate (95% CI) (%)	*P* value [c]	PEP occurrence, N	PEP rate (95% CI) (%)	*P* value [c]
-2		0/29	0 (0-11.9)	< 0.01	0/33	0 (0-10.6)	< 0.01
-1		0/9	0 (0-33.6)		0/5	0 (0-52.2)	
0		0/289	0 (0-1.3)		8/293	2.7 (1.2-5.3)	
1		6/140	4.3 (1.6-9.1)		5/160	3.1 (1.0-7.1)	
2		8/202	4.0 (1.7-7.7)		14/195	7.2 (4.0-11.8)	
3		13/150	8.7 (4.7-14.4)		8/158	5.1 (2.2-9.7)	
4		18/97	18.6 (11.4-27.7)		14/84	16.7 (9.4-26.4)	
5		17/83	20.5 (12.4-30.8)		14/71	19.7 (11.2-30.9)	
6		3/9	33.3 (7.5-70.1)		0/3	0 (0-70.8)	
7		1/4	25.0 (0.6-80.6)		1/3	33.3 (0.8-90.6)	
Risk classification	Risk score	PEP occurrence, N	PEP rate (95% CI) (%)	*P* value [c]	PEP occurrence, N	PEP rate (95% CI) (%)	*P* value [c]
Low	≤ 0	0/327	0 (0-1.1)	< 0.01	8/331	2.4 (1.0-4.7)	< 0.01
Moderate	1-3	27/492	5.5 (3.6-7.9)		27/513	5.3 (3.5-7.6)	
High	4-7	39/193	20.2 (14.8-26.6)		29/161	18.0 (12.4-24.8)	

PEP, post–endoscopic retrograde cholangiopancreatography pancreatitis; CI, confidence interval.

[a] There were missing data for 25 patients.

[b] There were missing data for 32 patients.

[c] The correlations between the risk score or classification and PEP occurrence were evaluated by the Cochran–Armitage test.

Table 4. Goodness of fit of the risk score model.

	Development cohort	Validation cohort
C-statistic (95% CI)	0.77 (0.72–0.82)	0.71 (0.64–0.78)
Hosmer–Lemeshow test, *p* value	0.59	0.40

CI, confidence interval.


Patients in whom ERCP was tried between
November 2020 – October 2022
N = 2176
Patients who did not meet the inclusion criteria
・Past history of choledochojejunostomy, N = 78
・Acute pancreatitis, N = 9
・Choledochoduodenal fistula, N = 8
・Difficulty in identifying the Vater papilla, N = 4
・Past history of pancreatojejunostomy, N = 2
・Past history of pancreatogastrostomy, N = 1
Patients who were involved in the analyses
N = 2074
Development cohort
N = 1037
Validation cohort
N = 1037

Preprocedural risk score for Post-ERCP pancreatitis

1. Please check the corresponding items and calculate the total score.

Risk factors	Points
☐ Female sex	1
☐ Native papilla of Vater	2
☐ Pancreatic calcification on imaging	-2
☐ IPMN	2
☐ Planned pancreatic duct procedures	2

Total ☐ points

2. Please find the predictive post-ERCP pancreatitis rate according to the total score.

Total points	Risk group	Predictive post-ERCP pancreatitis rate
≤ 0	Low	0-2%
1-3	Moderate	5%
4-7	High	18-20%

※The post-ERCP pancreatitis rate might change due to the actual ERCP procedure performed.